# E15 VC

> E15 VC is a VC fund in Central backing Health Care and Medical. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 11
- Last investment: Feb 2025
- Lead investor: 45%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/13460693/
- Website: http://www.e15vc.com
- Facebook: https://www.facebook.com/e15vc/

E15 VC is a stage and geographically agnostic venture capital firm

## Contacts

5 contacts available for E15 VC. Shizune tracks 2 team members at E15 VC. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/e15vc?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.3M–$5M |
| Series A | $13M–$14M |
| Series D | $280M–$351M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 36% |
| Medical | 3 | 27% |
| Robotics | 2 | 18% |
| Biotechnology | 2 | 18% |
| mHealth | 1 | 9% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 27% |
| Series A | 2 | 18% |
| Series D | 2 | 18% |
| Pre-Seed | 1 | 9% |
| Series B | 1 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 45% |
| Ireland | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Philip Liang | Managing Partner | 5 | https://shizune.co/investors/profile/philip-liang |
| Shrikant Patnaik | Principal | 0 | https://shizune.co/investors/profile/shrikant-patnaik |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Eikon Therapeutics | Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $350.7M | Series D | Feb 26, 2025 |  |
| Fluent Metal | Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe. | $3.2M | Seed | Mar 14, 2024 |  |
| Eikon Therapeutics | Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $517.8M | Series B | Jan 06, 2022 |  |
| Vicarious Surgical | Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. | $142M | Post-IPO Equity | Sep 20, 2021 |  |
| Frankie Health | Frankie gets high-quality support to employees with a few clicks and without needing to tell anyone else about it and uses a proactive and personalized approach to mental healthcare with underlying predictive models. | $1.3M | Seed | Jan 11, 2021 |  |
| Vicarious Surgical | Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. | $13.2M | Series A | Aug 07, 2020 |  |
| Frankie Health | Frankie gets high-quality support to employees with a few clicks and without needing to tell anyone else about it and uses a proactive and personalized approach to mental healthcare with underlying predictive models. | $250K | Pre-Seed | Jul 01, 2019 |  |
| Home Bay Technologies | HomeBay is a guided solution that makes it easy for homeowners to market and sell their property without the use or cost of a listing agent.Homeowners can list their home for sale in less time than it takes to meet with a realtor. Home Bay then syndicate their listing to every site that matters from popular sites like Zillow, Trulia, Yahoo!Homes, and Realtor.com to thousands of local agency and brokerage sites.Sellers manage their listings, open tasks, open houses, showings, and the incoming buyer offers directly from their dashboard. They can also receive and counter buyer offers with guided, in-form intelligence that is localized to their zip code. This guided transaction experience is akin to TurboTax, but applied to real estate forms. | $13.5M | Series A | Jan 03, 2019 |  |
| Auris Health | Auris Health engages in the development of robotics technology for medical applications. The company designs a novel dual-arm micro-surgical system for ophthalmic surgery. The company focuses on transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. It wasfounded in 2007 and headquartered in Redwood City, California. | $220M | Series E | Nov 28, 2018 |  |
| Auris Health | Auris Health engages in the development of robotics technology for medical applications. The company designs a novel dual-arm micro-surgical system for ophthalmic surgery. The company focuses on transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. It wasfounded in 2007 and headquartered in Redwood City, California. | $280.2M | Series D | Aug 04, 2017 |  |

10 of 11 investments shown.

## Co-investors
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 5 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 4 deals together
- [Innovation Endeavors](https://shizune.co/investors/profile/innovation-endeavors) — VC Fund, 3 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 3 deals together
- [AME Cloud Ventures](https://shizune.co/investors/profile/ame-cloud-ventures) — VC Fund, 2 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)
- [SaaS VC Funds in Ireland](https://shizune.co/investors/saas-vc-funds-ireland)
- [SaaS Investors in Ireland](https://shizune.co/investors/saas-investors-ireland)
- [Wellness Investors in Ireland](https://shizune.co/investors/wellness-investors-ireland)
- [Wellness VC Funds in Ireland](https://shizune.co/investors/wellness-vc-funds-ireland)

## FAQ

### What does E15 VC invest in?

E15 VC invests primarily in Health Care, Medical and Robotics startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is E15 VC's check size?

E15 VC typically joins rounds of $1.3M–$5M at Seed, $13M–$14M at Series A and $280M–$351M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds E15 VC participates in.

### How do I contact E15 VC?

Public channels for E15 VC include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at E15 VC?

The team at E15 VC includes Philip Liang (Managing Partner) and Shrikant Patnaik (Principal). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co